Edition:
United Kingdom

BioArctic AB (BIOAb.ST)

BIOAb.ST on Stockholm Stock Exchange

79.25SEK
12:58pm BST
Change (% chg)

-1.25kr (-1.55%)
Prev Close
80.50kr
Open
80.30kr
Day's High
80.30kr
Day's Low
78.15kr
Volume
20,125
Avg. Vol
204,630
52-wk High
172.00kr
52-wk Low
20.60kr

Latest Key Developments (Source: Significant Developments)

BioArctic Receives Grant From Vinnova For Collaborative Research Project
Wednesday, 3 Apr 2019 

April 3 (Reuters) - BioArctic AB ::BIOARCTIC RECEIVES GRANT FROM VINNOVA FOR A COLLABORATIVE RESEARCH PROJECT TO INCREASE BRAIN UPTAKE OF ANTIBODIES.RECEIVED A NON-DILUTING GRANT OF MSEK 5 FROM SWEDEN'S INNOVATION AGENCY, VINNOVA.COLLABORATIVE RESEARCH PROJECT BETWEEN INDUSTRY AND ACADEMIA TO DEVELOP MULTI-SPECIFIC ANTIBODIES.RESEARCH PROJECT INVOLVES BIOARCTIC AND TWO ACADEMIC INSTITUTIONS AT UPPSALA UNIVERSITY, SWEDEN.  Full Article

BioArctic: Confirmatory Phase 3 Study In Early Alzheimer's Patients Starts In March 2019
Thursday, 7 Mar 2019 

March 7 (Reuters) - BioArctic AB ::EISAI ANNOUNCES TIMELINES FOR THE SINGLE CONFIRMATORY PHASE 3 STUDY WITH BAN2401 IN EARLY ALZHEIMER'S DISEASE.CONFIRMATORY PHASE 3 STUDY IN EARLY ALZHEIMER'S DISEASE PATIENTS WILL BE INITIATED IN MARCH 2019.FINAL READOUT OF PRIMARY ENDPOINT IS TARGETED FOR 2022.EISAI IS RESPONSIBLE FOR CLINICAL DEVELOPMENT OF BAN2401.  Full Article

Bioarctic Q4 EBIT Up At SEK 430.3 Million
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - BioArctic AB ::Q4 NET SALES SEK 515.3 MILLION VERSUS SEK 51.0 MILLION YEAR AGO.Q4 EBIT SEK 430.3 MILLION VERSUS SEK 14.7 MILLION YEAR AGO.BOARD OF DIRECTORS PROPOSES A DIVIDEND OF SEK 1.50 PER SHARE FOR FISCAL YEAR 2018.  Full Article

Bioarctic Q3 EBIT Rises To SEK 33.1 Million
Thursday, 8 Nov 2018 

Nov 8 (Reuters) - BioArctic AB ::Q3 NET REVENUE SEK 94.0 MILLION VERSUS SEK 31.5 MILLION YEAR AGO.Q3 EBIT SEK 33.1 MILLION VERSUS SEK 0.6 MILLION YEAR AGO.  Full Article

BioArctic: Additional Ban2401 Phase 2B Study Results In Early Alzheimer's Disease
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - AB ::BIOARCTIC ANNOUNCES ADDITIONAL BAN2401 PHASE 2B STUDY RESULTS IN EARLY ALZHEIMER'S DISEASE PRESENTED BY EISAI AT THE 2018 CTAD CONFERENCE.STATISTICALLY SIGNIFICANT BENEFITS WERE OBSERVED ON KEY EFFICACY ENDPOINTS AT 18 MONTH ON SLOWING PROGRESSION IN ALZHEIMER'S DISEASE COMPOSITE SCORE (ADCOMS).STATISTICALLY SIGNIFICANT BENEFITS WERE OBSERVED ON REDUCTION OF AMYLOID ACCUMULATED IN BRAIN AS MEASURED BY USING AMYLOID-PET AT HIGHEST TREATMENT DOSE.PRE-SPECIFIED ANALYSES SHOW GOOD TOLERABILITY PROFILE OF BAN2401 WITH DOSE-DEPENDENT, CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT EFFECTS ON SEVERAL CLINICAL ENDPOINTS.CO'S PARTNER EISAI IS CURRENTLY DISCUSSING NEXT STEPS FOR BAN2401 WITH REGULATORY AUTHORITIES.  Full Article

BioArctic Receives European Patent Protection
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - BioArctic AB ::BIOARCTIC RECEIVES EUROPEAN PATENT PROTECTION FOR A MEDICAL DEVICE FOR TREATMENT OF PATIENTS WITH COMPLETE SPINAL CORD INJURY.PATENT, EP 2 787 900 B1, WILL ENTER INTO FORCE ON OCTOBER 24, 2018..  Full Article

Bioarctic Q2 Operating Profit Amounted To Sek 6.4 Million
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - BioArctic AB ::APRIL-JUNE NET REVENUES FOR PERIOD AMOUNTED TO SEK 52.3 MILLION (32.0).APRIL-JUNE OPERATING PROFIT AMOUNTED TO SEK 6.4 MILLION (2.5).  Full Article

BioArctic Receives Regulatory Approval In Finland For Clinical Study
Tuesday, 10 Jul 2018 

July 10 (Reuters) - BioArctic AB ::BIOARCTIC RECEIVES REGULATORY APPROVAL IN FINLAND FOR A CLINICAL STUDY IN PATIENTS WITH COMPLETE SPINAL CORD INJURY.APPROVAL MEANS THAT BIOARCTIC HAS RECEIVED APPROVALS IN ALL COUNTRIES PLANNED TO PARTICIPATE IN STUDY.  Full Article

Bioarctic Says Positive Topline Results Of Ban2401 Phase 2B At 18 Months In Early Alzheimer's Disease
Friday, 6 Jul 2018 

July 5 (Reuters) - BioArctic AB ::BIOARCTIC ANNOUNCES POSITIVE TOPLINE RESULTS OF BAN2401 PHASE 2B AT 18 MONTHS IN EARLY ALZHEIMER'S DISEASE.  Full Article

BioArctic Extends Research Collaboration With Uppsala University
Monday, 14 May 2018 

May 14 (Reuters) - BioArctic AB ::BIOARCTIC EXTENDS THE RESEARCH COLLABORATION WITH UPPSALA UNIVERSITY REGARDING NEW ANTIBODY TECHNOLOGY.EXTENDED RESEARCH COLLABORATION CONCERNS TECHNOLOGIES FOR INCREASED PASSAGE ACROSS BLOOD-BRAIN BARRIER.WILL CONTRIBUTE FINANCIAL SUPPORT FOR A THREE YEAR POST-DOC RESEARCH POSITION..  Full Article